Alan Watt

The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Cambridge Biotechnology Ltd. is a wholly owned subsidiary of Biovitrum AB. The company's founders originate from a Pfizer Global Research & Development drug discovery team in what had previously been the Parke-Davis Neuroscience Research Centre. The founders, together with some key academic collaborators, created the company to exploit several opportunities in drug discovery as well as their world class 'gene to lead' drug discovery capability. The company has well equipped modern laboratory and office facilities situated on the Babraham Research Campus. This location allows the company to forge links with a host of world class research groups based in the Cambridge area. CBT is always looking to identify potential partner companies for both in-licensing and risk-sharing drug discovery ventures.

NeuroSolutions Ltd. provides flexible and skilled services to biopharmaceutical companies with a fast turnaround time. The private company is based in Coventry, UK. The British company has a large portfolio of clients, ranging from small start-ups to multinational pharmaceutical companies, which validates their quality, reliability, speed, and discretion. The company was founded by Kevin Lee. NeuroSolutions was acquired by NeuroSolutions /Private Group/ from OncoSil Medical Ltd. on August 11, 2010 for $0.72 million.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom.

Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ.

iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA.

Macomics Ltd. engages in research and experimental development on biotechnology. The company was founded by Jeffrey William Pollard and Luca Cassetta on November 6, 2018 and is headquartered in Edinburgh, the United Kingdom.

Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.

Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.

Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009.

Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022.

Epidarex Exeed Ltd. is a British biotechnology company that specializes in research and experimental development. The company is based in Edinburgh, UK. The company was founded in 2019 by Elizabeth Ann Roper and Henning Steinhagen, with Henning Steinhagen serving as the CEO since its inception.

Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge.

Matchpoint Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company aims to discover and develop precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. Matchpoint's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution. The company was founded by Jianwei Che, Edward Chouchani, Tinghu Zhang, Nathanael S. Gray, and the CEO is G. Andre Turenne.

Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.